The Medical Innovation Agenda for the 119th Congress

Zach Rothstein, Executive Director of AdvaMedDx, on why this year’s diagnostics programming comes at an inflection point for IVD leaders — with regulatory modernization, reimbursement reform, and breakthrough technologies creating unprecedented opportunities to shape the future of health care.

Washington, D.C.—AdvaMed, the Medtech Association, asked the US District Court for the District of Massachusetts to rule as a matter of law that independent sales agent (ISA) arrangements do not — by themselves — violate the Anti-Kickback Statute (AKS) and, accordingly, grant summary judgment in the Langer v Zimmer Biomet case.

WASHINGTON, D.C.—AdvaMed, the world’s largest trade association representing medtech innovators, today urged the Centers for Medicare and Medicaid Services (CMS) to fix “serious flaws” in its proposed rule to restart competitive bidding for durable medical equipment in Medicare, citing risks to patient safety, fewer product choices for beneficiaries, and cost increases that would result if the rule stands. 

Christopher L. White, Esq., AdvaMed’s General Counsel & Chief Policy Officer, on why this year’s legal, compliance & regulatory programming is mission-critical as medtech leaders navigate uncertainty, shifting enforcement priorities, and a rapidly changing global legal landscape.

DeChane Dorsey, Executive Director of AdvaMed Accel and a  leading voice for early-stage innovation, to explore why this year’s programming is especially critical for small companies and entrepreneurs.

Thousands of K-12 students returning to school this fall will face a cell phone use ban during instructional hours. Diabetes monitoring deserves an exception.

WASHINGTON, D.C.—AdvaMed, the Medtech Association, is among 67 stakeholder groups, including patient advocacy groups and state medtech and life sciences associations, urging the Centers for Medicare and Medicaid Services (CMS) to create a timely, streamlined pathway for Medicare patients to access FDA-authorized breakthrough medical technology. 

Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.